Cargando…
Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer
PURPOSE: Immunotherapy has become widely applied in non-small cell lung cancer (NSCLC) patients. However, the relatively low response rate of immunotherapy monotherapy restricts its application. Combination therapy improves the response rate and prolongs patient survival; however, adverse events (AE...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459232/ https://www.ncbi.nlm.nih.gov/pubmed/36091128 http://dx.doi.org/10.3389/fonc.2022.938827 |